Artwork

Content provided by 7investing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 7investing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

United Therapeutics: Leading a Biotech Revolution

10:32
 
Share
 

Manage episode 438173737 series 2714551
Content provided by 7investing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 7investing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

United Therapeutics (Nasdaq: UTHR) is a very smart, very innovative, and very profitable company.

First it treated an untreatable disease. Now it's disrupting the entire organ transplant industry.

In today's show, 7investing CEO Simon Erickson introduces United Therapeutics, describing why the company was created and its five commercially-approved drugs.

He also explains how its four synthetic organ programs could disrupt the entire organ transplant market.

See why United Therapeutics is a stock that should be on your radar. To join our free email list, visit 7investing.com/email.

  continue reading

459 episodes

Artwork
iconShare
 
Manage episode 438173737 series 2714551
Content provided by 7investing. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 7investing or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

United Therapeutics (Nasdaq: UTHR) is a very smart, very innovative, and very profitable company.

First it treated an untreatable disease. Now it's disrupting the entire organ transplant industry.

In today's show, 7investing CEO Simon Erickson introduces United Therapeutics, describing why the company was created and its five commercially-approved drugs.

He also explains how its four synthetic organ programs could disrupt the entire organ transplant market.

See why United Therapeutics is a stock that should be on your radar. To join our free email list, visit 7investing.com/email.

  continue reading

459 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide